Cargando…
Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections
Due to the lack of an effective therapeutic treatment to flavivirus, dengue virus (DENV) nonstructural protein 1 (NS1) has been considered to develop a vaccine owing to its lack of a role in antibody-dependent enhancement (ADE). However, both NS1 and its antibody have shown cross-reactivity to host...
Autores principales: | Sootichote, Rochanawan, Puangmanee, Wilarat, Benjathummarak, Surachet, Kowaboot, Siriporn, Yamanaka, Atsushi, Boonnak, Korbporn, Ampawong, Sumate, Chatchen, Supawat, Ramasoota, Pongrama, Pitaksajjakul, Pannamthip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855337/ https://www.ncbi.nlm.nih.gov/pubmed/36672734 http://dx.doi.org/10.3390/biomedicines11010227 |
Ejemplares similares
-
Antibody germline characterization of cross-neutralizing human IgGs against 4 serotypes of dengue virus
por: Pitaksajjakul, Pannamthip, et al.
Publicado: (2014) -
Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity
por: Injampa, Subenya, et al.
Publicado: (2017) -
Genomic studies of envelope gene sequences from mosquito and human samples from Bangkok, Thailand
por: Pitaksajjakul, Pannamthip, et al.
Publicado: (2016) -
Combining Immunoassays to Identify Zika Virus Infection in Dengue-Endemic Areas
por: Sittikul, Pichamon, et al.
Publicado: (2022) -
Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012
por: Yamanaka, Atsushi, et al.
Publicado: (2021)